Valuation: Biodesix, Inc.

Market Cap 236M 204M 192M 174M 327M 22.58B 332M 2.25B 881M 11.3B 885M 866M 37.62B P/E 2026 *
-8.36x
P/E 2027 * -13.4x
Enterprise Value 236M 204M 192M 174M 327M 22.58B 332M 2.25B 881M 11.3B 885M 866M 37.62B EV / Sales 2026 *
2.11x
EV / Sales 2027 * 1.75x
Free-Float
55%
Yield 2026 *
-
Yield 2027 * -
1 day-3.91%
1 week-8.10%
Current month+5.38%
1 month+10.65%
3 months+56.77%
6 months+77.72%
Current year+228.53%
1 week 22
Extreme 22
25.27
1 month 19.09
Extreme 19.09
25.52
Current year 5.26
Extreme 5.26
25.52
1 year 5.26
Extreme 5.26
25.52
3 years 3.44
Extreme 3.436
44.2
5 years 3.44
Extreme 3.436
204.4
10 years 3.44
Extreme 3.436
639.8
Manager TitleAgeSince
Chief Executive Officer 54 2019-12-31
Director of Finance/CFO 46 2017-03-31
Chief Tech/Sci/R&D Officer - 2015-12-31
Director TitleAgeSince
Chairman 79 2020-09-13
Director/Board Member 53 2011-12-31
Director/Board Member 59 2020-03-31
Date Insider Type Main position Quantity % Market Cap.
8/12/26 Buy 15,000 0.1875%
8/11/26 Buy 13,700 0.1712%
6/30/26 Fiscal year

Chairman

2,722 0.0340%
Change 5-day change 1-year change 3-year change Capi.($)
-3.91%-8.10%+162.82%-26.03% 245M
-0.79%-0.33%+93.42%+492.57% 45.29B
-0.36%-0.07%+19.11%+50.25% 26.22B
+2.04%+5.47%-18.70%-27.07% 8.01B
-2.77%-3.29%+11.37%+148.34% 5.98B
+1.28%-2.49%+10.91%+69.62% 3.28B
-1.36%-6.61%-39.36%+1,474.02% 2.31B
-1.61%-3.81%+154.81%+17.34% 2.08B
-0.38%-8.01%-6.77%-54.13% 2B
-1.10%-2.90%+27.38%+18.91% 1.9B
Average -0.88%-2.48%+41.50%+216.38% 9.73B
Weighted average by Cap. -0.52%-0.54%+51.33%+286.53%

Financials

2026 *2027 *
Net sales 112M 96.7M 90.98M 82.69M 156M 10.73B 158M 1.07B 418M 5.37B 420M 411M 17.87B 135M 116M 109M 99.43M 187M 12.9B 190M 1.28B 503M 6.45B 505M 494M 21.49B
Net income -27.54M -23.79M -22.38M -20.34M -38.26M -2.64B -38.82M -263M -103M -1.32B -103M -101M -4.4B -19.47M -16.82M -15.82M -14.38M -27.05M -1.87B -27.45M -186M -72.75M -933M -73.11M -71.52M -3.11B
Net Debt - -
Logo Biodesix, Inc.
Biodesix, Inc. is a diagnostic solutions company. The Company's business includes Biodesix Lung Diagnostic Testing and Biodesix Development Services. Its Biodesix Lung Diagnostic Testing provides lung diagnostic testing services for healthcare providers through five blood-based tests. Its Biodesix Development Services supports global biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that enable the development of diagnostic tests, tools, and therapeutics. The Company offers Nodify Lung tests and IQLung tests that assess cancer risk and provide treatment guidance following a lung cancer diagnosis. The Nodify Lung tests include Nodify CDT and Nodify XL2 tests, which evaluate the risk of lung cancer in lung nodules. The GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests are used in the diagnosis of lung cancer to detect tumor mutations and assess the patient’s immune system status.
Employees
334
Date Price Change Volume
26-08-18 US$22.34 -3.91% 106,760
26-08-17 US$23.25 -3.12% 68,433
26-08-14 US$24.00 +0.88% 72,432
26-08-13 US$23.79 -1.78% 50,022
26-08-12 US$24.22 -0.37% 91,655
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
22.34USD
Average target price
34.00USD
Spread / Average Target
+52.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDSX Stock